03:54 PM EST - Algernon Pharmaceuticals Inc. : iHas received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval, for an investigator-led, Phase 2 COVID-19 clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist. Algernon Pharmaceuticals Inc.
shares AGN:CSX are trading up $0.035 at $0.49.
